IL4R and asthma: Moreover, the efficacy of a humanized monoclonal antibody against IL-4Rα (dupilumab) in the treatment of severe T2-high asthma and CRSwNP validates the biological importance of IL-4Rα–inducible products in disease pathophysiology (10, 11), although the relative contributions of each remain less clear.